pharma · Non-small Cell Lung Cancer · Epilepsy
Eisai
Eisai Co.,
Eisai is a pharma organization headquartered in Tokyo, JP. Primary therapeutic focus areas include Non-small Cell Lung Cancer, Epilepsy, colorectal cancer, melanoma, hepatocellular carcinoma, Amyotrophic Lateral Sclerosi
Company details
- Status
- Public
- HQ
- Tokyo, Japan, JP
- Employees
- 41
- Programs
- 22
- Drugs
- 31
- Patents
- 0
Quick answer
Eisai is a pharma organization headquartered in Tokyo, JP. Primary therapeutic focus areas include Non-small Cell Lung Cancer, Epilepsy, colorectal cancer, melanoma, hepatocellular carcinoma, Amyotrophic Lateral Sclerosis (ALS), Cancer: Solid Tumors. NovaPharmaNews links 22 clinical program(s), 4 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: phase 2 (11), phase 3 (7), phase 1 (4).
Company snapshot
Eisai’s Corporate Concept is “to give first thought to patients and people in the daily living domain, and to increase the benefits that health care provides.” Under this Concept (also known as human health care (hhc) Concept), we aim to effectively achieve social good in the form of relieving anxiety over health and reducing health disparities. With a global network of R&D facilities, manufacturi
- 6 approved product(s) across US/EU regulatory metadata.
- 22 active pipeline program(s) linked via ClinicalTrials.gov.
- 22 trial update(s) in the last 12 months.
Public regulatory, clinical, patent, and corporate records for Eisai. Not investment advice.
Catalysts
Upcoming readouts, regulatory dates, and congress activity.
- trial_data
Eisai's Leqembi Sales Forecast: Projecting Blockbuster Status in Alzheimer's
- approval
FDA Approves Generic Eribulin Mesylate for Metastatic Breast Cancer
- approval
Eisai's Leqembi Sales Forecast: A Turning Point?
- approval
Biogen and Eisai expand Leqembi access with subcutaneous maintenance dosing
Recent coverage
Biogen and Eisai expand Leqembi access with subcutaneous maintenance dosing
Biogen and Eisai have expanded LEQEMBI access in the U.S. with subcutaneous maintenance dosing, following FDA approval of the BLA in August 2025. The move could improve convenience, reduce infusion-related burden, and shape investor expectations for Eisai and Biogen stock.
FDA Approves Generic Eribulin Mesylate for Metastatic Breast Cancer
The U.S. Food and Drug Administration (FDA) has approved an abbreviated new drug application (ANDA) for generic eribulin mesylate injection. This approval offers a new therapeutic option for patients with pretreated metastatic breast cancer and unresectable or metastatic liposarcoma.
Eisai's Leqembi Sales Forecast: A Turning Point?
Structured plan for Eisai's Leqembi Sales Forecast: A Turning Point?
Eisai's Leqembi Sales Forecast: Projecting Blockbuster Status in Alzheimer's
Eisai projects significant growth for its Alzheimer's treatment, Leqembi, with sales forecasts indicating a strong path toward blockbuster status. This analysis explores the drivers behind this projection and its strategic implications for the pharmaceutical industry.
Top assets
Lead pipeline drugs
- Marketed / approved
- Marketed / approved
- Marketed / approved
- Marketed / approved
Active clinical programs
- Phase 3
- Phase 3
- Phase 3
- Phase 3
Momentum
Proprietary activity score for Eisai.
2 active signals
Signal breakdown
- Clinical trials
- Nova articles
- Patents filed
- FDA actions
- SEC filings
- Conference presentations
- Pipeline advances
Competitor landscape
Therapeutic-area overlap peers from registry and pipeline signals.
- Peer + 0 momentum
- Peer + 0 momentum
- Peer + 0 momentum
Recent activity
Latest pipeline, patent, and corporate events for Eisai.
- Clinical update
- Clinical update
- Clinical update
- Clinical update
- Clinical update
Quick answers
Common questions about this sponsor — for analysts and search.
-
What is Eisai?
-
Is Eisai publicly traded?
-
What drugs does Eisai develop or market?
-
What are the latest developments for Eisai?
-
What therapeutic areas does Eisai focus on?
Therapeutic focus
Therapeutic area distribution
Pipeline concentration by therapeutic area from linked clinical programs.